United Laboratories expands ophthalmic portfolio with new drug approvals

The United Laboratories International Holdings Limited announced the approval of Levofloxacin Eye Drops (0.488% (5ml:24.4mg)) by China's National Medical Products Administration, securing drug approval number H20256135. This third-generation quinolone antibiotic, indicated for various ophthalmic conditions, is listed in Category A of the National Medical Insurance Drug List (2024 Edition). This approval expands the company's ophthalmic portfolio and reinforces its leading position in anti-infective treatment.

Additionally, the company also secured approval for Moxifloxacin Hydrochloride Eye Drops, with specifications of 0.5% (3ml:15mg) and 0.5% (5ml:25mg), under drug approval numbers H20256128 and H20256129. This fourth-generation quinolone antibiotic is designed to treat bacterial conjunctivitis and is listed in Category B of the National Medical Insurance Drug List (2024 Edition). Both approvals were for products submitted by Zhuhai United Laboratories Co., Ltd, Zhongshan Branch, a wholly-owned subsidiary.

These approvals underscore the company's commitment to developing new products and delivering comprehensive therapeutic solutions for clinical use, aiming to generate greater returns for the company and its shareholders. The company’s board anticipates these new products will enhance its competitive edge in the market.